RECRUITING

Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial tests whether provider-mediated communication of genetic testing results to at-risk relatives of cancer patients can help improve genetic counseling and testing rates. Approximately 15% of people with cancer have an inherited form of cancer due to changes in a gene that they have inherited from one of their parents. These changes increase a person's risk for developing cancer. Most people who have an inherited harmful change in a cancer risk gene don't know that they have it and are therefore not able to get the health care that they need. The primary reason for this problem has been a lack of genetic counseling and testing for cancer patients and patients with a strong family history of cancer. Another reason for this lack of awareness is that, when cancer runs in a family, the patient who carries the gene change usually has to communicate the genetic risk information to their family members. When this process doesn't work well, family members may not know that they need to get genetic testing and then may not get potentially life-saving care. Provider-mediated contact to discuss genetic test results may help improve rates of genetic testing among at-risk relatives of patients with a family cancer syndrome.

Official Title

Family HOPE Study (Hereditary Lynch Syndrome Opportunities for Participation &Amp; Engagement)

Quick Facts

Study Start:2023-02-14
Study Completion:2025-12-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05772130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing
  2. * PATIENTS: Have an pathogenic/ likely pathogenic germline variant
  3. * PATIENTS: Fluent in English
  4. * PATIENTS: Age \>= 18 years
  5. * PATIENTS: Willing to provide contact information for eligible first-degree relatives
  6. * PATIENTS: \>= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America
  7. * FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study
  8. * FIRST-DEGREE RELATIVES: First-degree relative of proband
  9. * FIRST-DEGREE RELATIVES: Resides within the United States
  10. * FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant
  11. * FIRST-DEGREE RELATIVES: Are fluent in English
  12. * FIRST-DEGREE RELATIVES: Age \>= 18 years
  1. * PATIENTS: Unable to provide informed consent
  2. * PATIENTS: =\< 2 at-risk first-degree relatives who are eligible for genetic testing and/or reside within the United States
  3. * PATIENTS: Unwilling to provide contact information for family members
  4. * FIRST-DEGREE RELATIVES: Unable or unwilling to provide informed consent
  5. * FIRST-DEGREE RELATIVES: Have undergone genetic testing for the known familial variant
  6. * FIRST-DEGREE RELATIVES: Resides outside of the United States

Contacts and Locations

Principal Investigator

Stacy W Gray
PRINCIPAL_INVESTIGATOR
City of Hope Medical Center

Study Locations (Sites)

City of Hope Medical Center
Duarte, California, 91010
United States

Collaborators and Investigators

Sponsor: City of Hope Medical Center

  • Stacy W Gray, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-02-14
Study Completion Date2025-12-14

Study Record Updates

Study Start Date2023-02-14
Study Completion Date2025-12-14

Terms related to this study

Additional Relevant MeSH Terms

  • Hematopoietic and Lymphoid System Neoplasm
  • Hereditary Malignant Neoplasm
  • Malignant Solid Neoplasm